Jason E. Chan

1.6k total citations
20 papers, 548 citations indexed

About

Jason E. Chan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jason E. Chan has authored 20 papers receiving a total of 548 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Jason E. Chan's work include CAR-T cell therapy research (5 papers), Sarcoma Diagnosis and Treatment (5 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Jason E. Chan is often cited by papers focused on CAR-T cell therapy research (5 papers), Sarcoma Diagnosis and Treatment (5 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Jason E. Chan collaborates with scholars based in United States, Switzerland and Belgium. Jason E. Chan's co-authors include Richard D. Kolodner, Svetlana Pacifico, Farshad Fotouhi, Victor J. DiRita, Trey Ideker, Huamei Zhang, Russell L. Finley, Jingkai Yu, Philip Andrews and Jodi R. Parrish and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Jason E. Chan

19 papers receiving 541 citations

Peers

Jason E. Chan

ONCOL

PRM

Caroline C. Kim United States

Yosr Hamdi Tunisia

Shirish Paranjpe United States

Monique Albert Canada

Mohammed Hassan Saudi Arabia

Robin Gross United States

Nasser Fotouhi‐Ardakani Canada

Aixin Li China

Allison Vitsky United States

María González‐Pons Puerto Rico

Caroline C. Kim United States

Jason E. Chan

292 ×1.1

404 ×1.9

ONCOL

14 ×0.1

22 ×0.3

31 ×0.6

PRM

Citations per year, relative to Jason E. Chan Jason E. Chan (= 1×) peers Caroline C. Kim

Countries citing papers authored by Jason E. Chan

Since Specialization

Citations

This map shows the geographic impact of Jason E. Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason E. Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason E. Chan more than expected).

Fields of papers citing papers by Jason E. Chan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jason E. Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason E. Chan. The network helps show where Jason E. Chan may publish in the future.

Co-authorship network of co-authors of Jason E. Chan

This figure shows the co-authorship network connecting the top 25 collaborators of Jason E. Chan. A scholar is included among the top collaborators of Jason E. Chan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jason E. Chan. Jason E. Chan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chan, Jason E., et al.. (2026). Critical role for a high-plasticity cell state in lung cancer. Nature. 651(8104). 231–241.

Chan, Jason E., William D. Tap, Cristina R. Antonescu, et al.. (2025). Deep-Learning Tool ScVital Enables Species-Agnostic Integration of Cancer Cell States. Cancer Research. 86(4). 858–872. 1 indexed citations

Kelly, Ciara M., Mary Louise Keohan, Jason E. Chan, et al.. (2024). 1752P A retrospective single-center study of outcomes to immune checkpoint blockade-based therapy in leiomyosarcoma. Annals of Oncology. 35. S1045–S1045. 1 indexed citations

Dickson, Mark A., Sujana Movva, Ciara M. Kelly, et al.. (2024). 1720MO A phase II study of palbociclib combined with the PD-1 inhibitor retifanlimab in patients with advanced dedifferentiated liposarcoma. Annals of Oncology. 35. S1031–S1031. 4 indexed citations

Lee, Jun Ho, Francisco J. Sánchez‐Rivera, Lan He, et al.. (2024). TGF-β and RAS jointly unmask primed enhancers to drive metastasis. Cell. 187(22). 6182–6199.e29. 29 indexed citations

Kelly, Ciara M., Viswatej Avutu, Lauren B. Banks, et al.. (2024). Phase I trial of CRD3874-SI, a systemically administered STING agonist, in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS2690–TPS2690. 2 indexed citations

Rosenbaum, Evan, Kenneth Seier, Martina Bradić, et al.. (2023). Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas. Cancer Research Communications. 3(10). 2118–2125. 6 indexed citations

Rosenbaum, Evan, Li‐Xuan Qin, Mark A. Dickson, et al.. (2023). Interim results of a phase II trial of first line retifanlimab (R) plus gemcitabine and docetaxel (GD) in patients (pts) with advanced soft tissue sarcoma (STS).. Journal of Clinical Oncology. 41(16_suppl). 11518–11518. 3 indexed citations

D’Angelo, Sandra P., Evan Rosenbaum, Mark A. Dickson, et al.. (2023). A phase II study of palbociclib combined with retifanlimab in patients with advanced dedifferentiated liposarcoma.. Journal of Clinical Oncology. 41(16_suppl). TPS11590–TPS11590. 1 indexed citations

10.

Torborg, Stefan, et al.. (2022). Cellular and molecular mechanisms of plasticity in cancer. Trends in cancer. 8(9). 735–746. 38 indexed citations

11.

Rosenbaum, Evan, Li‐Xuan Qin, Katherine A. Thornton, et al.. (2022). A phase I/II trial of the PD-1 inhibitor retifanlimab (R) in combination with gemcitabine and docetaxel (GD) as first-line therapy in patients (Pts) with advanced soft-tissue sarcoma (STS).. Journal of Clinical Oncology. 40(16_suppl). 11516–11516. 5 indexed citations

12.

Chan, Jason E., et al.. (2022). Lineage plasticity in prostate cancer depends on FGFR and JAK/STAT inflammatory signaling. European Journal of Cancer. 174. S4–S5. 2 indexed citations

13.

Nacev, Benjamin A., Martina Bradić, Allison L. Richards, et al.. (2022). Presence of immune infiltrates, increased expression of transposable elements, and viral response pathways in sarcoma associate with response to checkpoint inhibition.. Journal of Clinical Oncology. 40(16_suppl). 11510–11510. 1 indexed citations

14.

Rosenbaum, Evan, Sujana Movva, Ciara M. Kelly, et al.. (2021). A phase 1b study of avelumab plus DCC-3014, a potent and selective inhibitor of colony stimulating factor 1 receptor (CSF1R), in patients with advanced high-grade sarcoma.. Journal of Clinical Oncology. 39(15_suppl). 11549–11549. 9 indexed citations

15.

Jee, Justin, Michael B. Foote, Melissa Lumish, et al.. (2020). Chemotherapy and COVID-19 Outcomes in Patients With Cancer. Journal of Clinical Oncology. 38(30). 3538–3546. 173 indexed citations

16.

Chen, Xi, Edward K. Avila, Elena Mead, et al.. (2018). NCMP-07. CLINICAL NEUROLOGICAL FEATURES AND ELECTROGRAPHIC PATTERNS OF PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA TREATED WITH AXICABTAGENE CILOLEUCEL AT MEMORIAL SLOAN KETTERING CANCER CENTER (MSKCC). Neuro-Oncology. 20(suppl_6). vi194–vi195. 1 indexed citations

17.

Chan, Jason E. & Richard D. Kolodner. (2012). Rapid Analysis of Saccharomyces cerevisiae Genome Rearrangements by Multiplex Ligation–Dependent Probe Amplification. PLoS Genetics. 8(3). e1002539–e1002539. 15 indexed citations

18.

Putnam, Christopher D., et al.. (2012). Bioinformatic identification of genes suppressing genome instability. Proceedings of the National Academy of Sciences. 109(47). E3251–9. 23 indexed citations

19.

Chan, Jason E. & Richard D. Kolodner. (2011). A Genetic and Structural Study of Genome Rearrangements Mediated by High Copy Repeat Ty1 Elements. PLoS Genetics. 7(5). e1002089–e1002089. 59 indexed citations

20.

Parrish, Jodi R., Jingkai Yu, Guozhen Liu, et al.. (2007). A proteome-wide protein interaction map for Campylobacter jejuni. Genome biology. 8(7). R130–R130. 175 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact